APAC Pyrogen Testing Market Size & Growth (2019 - 2024)
The size of the APAC Pyrogen Testing Market was worth $127.30 million in 2019 and estimated to be growing at a CAGR of 16.7%, to reach $275.54 million by 2024.
Pyrogens are substances produced by the bacterium, when released into blood produces fever. Pyrogen testing is used to ensure these toxic substances are absent in the body.
Pyrogen contamination can be caused due to various reasons such as environmental factors, through contaminated solute, solvent, container and apparatus. When contaminated drugs are injected into the bloodstream the toxins bypass normal defence mechanism to overcome these white blood cells in the body start releasing another form of pyrogen causing high fever which in some cases may even lead to shock and death
Asia-Pacific Pyrogen testing market is expected to show significant market growth owing to factors such as the increasing number of biologic products and increasing emphasis on Research and development.
However stringent regulatory policies, unclear reimbursement issues and limited awareness about the advanced testing procedures are the major factors restraining the growth of the market.
This research report segmented and sub-segmented into the following categories:
Regionally, Asia-Pacific is estimated to be the fastest-growing region due to the continuously growing population, and increasing healthcare expenditure. China is estimated to be the largest market within the region owing to its high population while India is the fastest growing due to increasing disposable income.
Companies playing a dominating role in the APAC Pyrogen Testing Market profiled in this report are Associates of Cape Cod, Inc., Lonza Group, Merck Kgaa, Thermo Fisher Scientific, Ellab A/S, Genscript, Hyglos GmbH, Charles River Laboratories, Inc., Wako Chemicals USA, Inc. and WUXI Pharmatech (Cayman) Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Product
5.1.1 Kits and Reagents
5.1.2 Services
5.1.3 Instruments
5.2 By Application
5.2.1 Pharmaceutical and Biological Manufacturing
5.2.2 Medical Device Manufacturing
5.2.3 Other Applications
5.3 By Test Type
5.3.1 LAL Tests
5.3.1.1 Chromogenic Tests
5.3.1.2 Turbidimetric Tests
5.3.1.3 Gel Clot Tests
5.3.2 In-Vitro Tests
5.3.3 Rabbit Tests
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Associates of Cape Cod, Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Charles River Laboratories, Inc.
8.3 Lonza Group
8.4 Merck Kgaa
8.5 Ellab A/S
8.6 Genscript
8.7 Hyglos GmbH
8.8 Thermo Fisher Scientific, Inc.
8.9 Wako Chemicals USA, Inc.
8.10 WUXI Pharmatech (Cayman) Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
